Medication info
Trusitam Extended-Release Tablet 50/750 mg (Sitagliptin, Metformin)

Trusitam Extended-Release Tablet 50/750 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›750mg / 1 tablet
Manufacturer / importer
Boryung Pharmaceutical Co., Ltd.
Appearance
Bright green, oval-shaped, biconvex extended-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202300020 · Approved 2023.01.02 · Insurance code 641908210

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg, 50/750 mg, or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their existing metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their existing doses of sitagliptin and metformin. - Patients previously taking immediate-release metformin 850 mg or 1000 mg twice daily may start with this medicine 50/1000 mg extended-release tablets, 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined in consideration of the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Boryung Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes. Sitagliptin and metformin work together to enhance the effects of dietary intervention and physical activity. This allows for more effective management of blood sugar levels. Regular use improves blood sugar control and plays a critical role in diabetes management. This medication is used to assist diet and exercise in the treatment of diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg, 50/750 mg, or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their existing metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their existing doses of sitagliptin and metformin. - Patients previously taking immediate-release metformin 850 mg or 1000 mg twice daily may start with this medicine 50/1000 mg extended-release tablets, 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined in consideration of the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication is used in diabetes treatment and contains two active ingredients. The first ingredient is sitagliptin, which can rarely cause allergic reactions or serious skin conditions, including pancreatitis; therefore, discontinuation should occur immediately if symptoms appear, and a doctor should be consulted. The second ingredient is metformin, which should not be administered to patients with poor kidney function or certain acute conditions. There is a risk of lactic acidosis, a rare side effect associated with this medication, which can be life-threatening, so symptoms should be reported to healthcare professionals immediately. This medication should not be used in patients with reduced kidney function, patients experiencing severe infections or dehydration, or women who are pregnant or breastfeeding. Additionally, it should be temporarily discontinued during certain periods before and after surgery, and caution is necessary for patients with poor nutritional status or impaired liver function. During treatment, hypoglycemic symptoms may occur, so patients, especially those taking other hypoglycemic agents, should carefully monitor their blood sugar levels. Symptoms of hypoglycemia include dizziness, cold sweats, and tremors. Patients taking this medication should undergo regular kidney function and blood tests, and it is advisable to check vitamin B12 levels as well. Alcohol consumption should be avoided as it can increase the risk of lactic acidosis. Due to potential drug interactions, patients taking other medications should consult their doctor or pharmacist, particularly when using medications that may affect kidney function. Elderly patients or those with compromised kidney function may require dosage adjustments, and this medication is not recommended for children or pregnant women. In cases of overdose, patients should seek medical attention immediately for appropriate treatment, which may include blood dialysis if necessary. If any unusual symptoms or discomfort occur while taking this medication, patients must inform their healthcare provider.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, bullous pemphigoid, myalgia, limb pain, back pain, epileptic lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, hypoglycemic episode, peripheral edema, anemia, rash, urticaria, cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, avoid storing it in extremely hot or cold locations, and it is recommended to keep it at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright green, oval-shaped, biconvex extended-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.